{"url_path":"/sec/xene/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-255396-index.html","accession_number":"0001193125-26-255396","cik":"0001582313","ticker":"XENE","issuer_name":"Xenon Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-255396-index.html","primary_entity_key":"0001582313","primary_entity_name":"Xenon Pharmaceuticals Inc."},"word_count":81,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d)\nExhibits\n\n \n\nExhibit Number\n\nDescription\n\n10.1\n\n[2026 Equity Incentive Plan and related form agreements.](xene-ex10_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\nXENON PHARMACEUTICALS INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 3, 2026\n\nBy:\n\n/s/ Thomas P. Kelly\n\n \n\n \n\n \n\nThomas P. Kelly\nChief Financial Officer"}